Editorial: Over the holiday period, the Guardian leader column is looking ahead at the themes of 2026. Today we examine how the White House’s war on vaccines has left the future of a key technology un ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of an advanced animal mRNA vaccine platform to accelerate the development ...

Scientists at MIT have discovered a method to restore lost strength to aging immune systems by using mRNA technology.

Wall Street edged higher on Tuesday, led by healthcare and technology stocks, extending the previous session's rally as ...

The study examined 180 patients with advanced lung cancer who received a COVID vaccine within 100 days before or after beginning immunotherapy, as well as 704 similar patients who did not. Vaccinated ...

Researchers have used an experimental mRNA therapy to make old immune cells in mice behave as if they were young again, ...

Research on mRNA vaccines have been under fire in the post-pandemic age, but these immunotherapies are showing promise in the ...

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...

Researchers found a way to boost aging immune systems by turning the liver into a temporary source of immune support signals ...

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA ...